Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.

Marjolein de Bruin-WellerAndrew E PinkAnnalisa PatriziGimenez-Arnau Ana MariaTove AgnerPierre-Paul Roquet-GravySilvia M FerrucciPetr ArenbergerAke SvenssonMarie L A SchuttelaarAudrey NosbaumShyamalie JayawardenaElena RizovaMarius ArdeleanuLaurent EckertZafer E Ozturk

Published in: The Journal of dermatological treatment (2021)

Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.

Keyphrases

atopic dermatitis
stem cells
drug induced
risk factors
combination therapy
replacement therapy
bone marrow